Healthcare - Biotechnology - NASDAQ - DE
$ 2.54
-4.87 %
$ 570 M
Market Cap
-1.97
P/E
CASH FLOW STATEMENT
-268 M
OPERATING CASH FLOW
-55.2 M
INVESTING CASH FLOW
231 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CureVac N.V.
| Net Income | -260 M |
| Depreciation & Amortization | 23.4 M |
| Capital Expenditures | -55.2 M |
| Stock-Based Compensation | 7.7 M |
| Change in Working Capital | -68.3 M |
| Others | 45.2 M |
| Free Cash Flow | -323 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (260.0) | (249.2) | (412.5) | (129.8) | (100.1) | (71.1) |
| Depreciation & Amortization | 23.4 | 23.7 | 15.7 | 10.7 | 7.2 | 3.8 |
| Deferred Income Tax | 0 | (1.6) | 199.0 | (2.9) | (0.8) | 52 K |
| Stock Based Compensation | 7.7 | 9.2 | 15.0 | 14.2 | 19.6 | (4.2) |
| Other Operating Activities | 29.3 | 57.2 | (480.7) | 51.6 | 9.9 | (1.5) |
| Change in Working Capital | (68.3) | (125.6) | (69.5) | 578.6 | (22.7) | (1.1) |
| Cash From Operations | (267.9) | (286.2) | (733.1) | 522.4 | (87.0) | (74.1) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (55.2) | (93.2) | (127.9) | (47.4) | (12.2) | (14.7) |
| Other Items | 0 | (0.3) | 0 | 2.1 | 40.4 | 10.5 |
| Cash From Investing Activities | (55.2) | (93.5) | (127.9) | (45.3) | 28.2 | (4.3) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | (30.9) | 0 | 0 | 0 |
| Total Debt Repaid | (5.2) | (4.2) | (28.2) | (47.9) | 68.0 | (0.1) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Financing Activities | 230.9 | 63.2 | 345.0 | 819.8 | 68.0 | (0.1) |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (93.3) | (315.7) | (511.1) | 1 291.9 | 9.3 | (78.3) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (323.1) | (379.4) | (861.0) | 475.1 | (99.2) | (88.8) |